Table 1.
Clinical and biochemical data of study participants.
| Control | HHcy | cblC-MMA | |
|---|---|---|---|
| Men [n (%)] | 30(52.6) | 9(60) | 21(50) |
| Age (years, median, 95% CI) | 10.0(6.7–12.0) | 16.0(14.5–17.5) | 6.5(3.8–9.7)& |
| Age of onset (years, median, 95% CI) | - | 14.0 (12.1–15.0) | 3.6 (0.8–5.5) & |
| Family history [n (%)] | - | 0 (0) | 4 (9.5)& |
| Creatinine (μmol/L, median, 95% CI) | 44 (37–48) | 65.5 (57.5–128.7)* | 31.4 (25.8–37.8) & |
| Urea (mmol/L, median, 95% CI) | 4 (3.3–4.1) | 6.98 (6.62–8.73)* | 5.06 (4.14–6.30)* |
| Proteinuria [n (%)] | 0 (0) | 12 (80)* | 10 (23.8)*& |
| Hematuria [n (%)] | 0 (0) | 9(60)* | 9 (21.4) *& |
| Normal IQ or DQ [n (%)] | 57 (100) | 15 (100) | 10 (23.8)*& |
| Mild cognitive impairment [n (%)] | 0 (0) | 0 (0) | 14 (33.3)*& |
| Moderate cognitive impairment [n (%)] | 0 (0) | 0 (0) | 12 (28.6)*& |
| Severe cognitive impairment [n (%)] | 0 (0) | 0 (0) | 6 (14.3)*& |
*
p < 0.05, compared with control group;
&
p < 0.05, compare with HHcy group. HHcy, non-inherited hyperhomocysteinemia. Continuous Data were shown as median with 95% CI.